Kindred Biosciences Announces Second Quarter 2017 Financial Results

San Francisco, CA (August 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2017 and provided updates on its programs. “We continue to look forward to our two upcoming approvals and launches. The commercial […]

Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting

Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting San Francisco, CA (August 4, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be sponsoring twenty veterinary students to attend the 2017 American Association of […]

Kindred Biosciences to Announce Second Quarter 2017 Financial Results

Kindred Biosciences to Announce Second Quarter 2017 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, August 7, 2017 San Francisco, CA (July 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today […]

KindredBio Announces Pricing of Public Offering

SAN FRANCISCO, July 12, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.50 per share, for a total offering amount of […]

KindredBio Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, California. (July 11, 2017) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the […]